YAVNE, Israel, June 02, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD ), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that an abstract highlighting the merits of NexoBrid ® in the treatment of severely burned hands was selected as “Best Poster Presentation” at the 52 nd Congress of the Spanish Society of Aesthetic, Plastic and Reconstructive Surgery (SECPRE). The SECPRE was held in Bilbao, Spain, and the presentation, titled “Functional Outcomes after Enzymatic Debridement of Hand Burns,” was delivered by Jose Ramon Martinez-Mendez, M.D., Ph.D., Chief of the burn unit of La Paz University Hospital in Madrid, Spain.
The presentation reported on 12 patients with intermediate to deep dermal burns of the hand, who underwent selective enzymatic eschar removal with NexoBrid. The study concluded that “Enzymatic debridement allowed for early functional rehabilitation of intermediate and deep dermal burned hands. This led to very good early hand function with no clinical differences between the burned and healthy hand, with a low rate of hypertrophic scarring.”
“We are particularly pleased to have a NexoBrid poster awarded this distinction at SECPRE as this congress is not only for burn specialists but encompasses all of aesthetic and reconstructive plastic surgery. This award marks the third consecutive year an abstract highlighting NexoBrid's merits is awarded the best presentation at a leading medical conference,” noted Gal Cohen, President and Chief Executive Officer of MediWound. “Severe hand burns are some of the most frequently burned areas and are also among the most challenging to treat as the hands are highly visible and functional areas, and due to the small counture of the fingers and the crowded and delicate structures underneath the burned skin, surgical treatment of burnt hands is difficult even for experienced burn specialists. Using NexoBrid to debride hand burns spared surgical, excisional debridement and grafting for the patients in this study, allowing for early functional rehabilitation, good hand function and less scarring than with surgical debridement and corroborates the data of previous studies. It is a great honor to have NexoBrid recognized by among this large audience of plastic surgeons in Spain that granted NexoBrid's minimal invasive approach with the best poster award. We look forward to continuing to foster and support evidence-based medicine to advance burn care.”
About the Spanish Society of Aesthetic, Plastic and Reconstructive Surgery (SECPRE) SECPRE is a scientific society that brings together specialists in plastic surgery who have become part of it for their merits in terms of training, knowledge, experience and ethics. Founded in 1956 with the aim of providing optimal quality care to patients and offer the highest levels of professionalism.
About NexoBrid
NexoBrid is an easy-to-use, topically-applied product that removes dead or damaged tissue, known as eschar, in approximately four hours without harming the surrounding healthy tissues. NexoBrid received marketing authorization from the European Medicines Agency for the removal of eschar in adults with deep partial and full-thickness thermal burns, is commercially available in Europe, Israel and Argentina. Representing a new paradigm in burn care management, NexoBrid demonstrated in clinical studies, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier than other modalities, without harming viable tissues. The removal of eschar or “debridement” is a critical first step in the successful healing of severe burns and chronic and other hard-to-heal wounds. With the current standard of care, burn eschar is removed either with existing topical agents that have been found to be minimally effective or that take a significantly longer period of time to work, or by resorting to non-selective excisional surgery, which is traumatic and may result in loss of blood and viable tissue necessitating further surgical treatments. The U.S. Phase 3 clinical trial and registration process for NexoBrid is being funded in whole or in part with federal funds under a contract with the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority.
About MediWound Ltd.
MediWound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid ® , received marketing authorization from the European Medicines Agency as well as the Israeli and Argentinian Ministries of Health, for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in Europe, Israel and Argentina. NexoBrid ® represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues.
MediWound's second innovative product, EscharEx ® is a topical biological drug being developed for debridement of chronic and other hard-to-heal wounds and is complementary to the large number of existing wound healing products, which require a clean wound bed in order to heal the wound. EscharEx ® contains the same proteolytic enzyme technology as NexoBrid ® , and benefits from the wealth of existing development data on NexoBrid ® . In two Phase 2 studies, EscharEx ® has demonstrated safety and efficacy in the debridement of chronic and other hard-to-heal wounds, within a few daily applications. For more information, please visit www.mediwound.com .
Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the US Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding the potential of NexoBrid ® to be a new paradigm in burn care management, our ability to leverage existing data for the development of EscharEx ® , and our expectations for the clinical development of both NexoBrid ® and EscharEx ® . In some cases, you can identify forward-looking statements by terminology such as "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," "predict," "potential," or the negative of these terms or other similar expressions. Forward-looking statements are based on MediWound's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors. In particular, you should consider the risks discussed under the heading "Risk Factors" in our annual report on Form 20-F for the year ended December 31, 2016 and information contained in other documents filed with or furnished to the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. The forward-looking statements made herein speak only as of the date of this announcement and MediWound undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
Anne Marie Fields Sharon Malka Senior Vice President Chief Financial and Operations Officer LHA Investor Relations MediWound 212-838-3777 ir@mediwound.co.il afields@lhai.com
